Skip to main content
Midas Edge

Passage BIO Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

PASG$3.43-13.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statements of Stockholders’ Equity

​​​​​​​​​​​​​​​​​
​ · ​ · Common stock · ​ · Additional · ​ · ​ · Accumulated other · ​ · ​ · Accumulated · ​ · ​ · ​
(in thousands, except share data) · Shares · Amount · paid‑in capital · ​ · ​ · comprehensive income (loss) · ​ · deficit · ​ · Total
Balance at April 1, 202461,611,796​$6$716,125​$(69)​$(611,179)​$104,883
Exercise of stock options and vesting of restricted stock units44,425​—35​—​—​35
Issuance of shares in connection with employee stock purchase plan​98,565​—50​—​—​​50
Unrealized gain (loss) on marketable securities—​——​2​—​2
Share‑based compensation expense—​—1,578​—​—​1,578
Net loss—​——​—​(15,991)​(15,991)
Balance at June 30, 202461,754,786​$6$717,788​$(67)​$(627,170)​$90,557
​​​​​​​​​​​​​​​​​
​​​​​​​​​​​​​​​​​
​​Common stock​Additional​​Accumulated other​​Accumulated​​​
(in thousands, except share data)SharesAmountpaid‑in capital​​comprehensive income (loss)​deficit​Total
Balance at January 1, 202454,944,130​$5$705,789​$(43)​$(594,468)​$111,283
Issuance of common stock under the ATM Facility, net of offering costs​6,000,000​​1​8,741​​—​​—​​8,742
Exercise of stock options and vesting of restricted stock units712,091​—35​—​—​35
Issuance of shares in connection with employee stock purchase plan​98,565​​—​50​​—​​—​​50
Unrealized gain (loss) on marketable securities—​——​(24)​—​(24)
Share‑based compensation expense—​—3,173​—​—​3,173
Net loss—​——​—​(32,702)​(32,702)
Balance at June 30, 202461,754,786​$6$717,788​$(67)​$(627,170)​$90,557

Statements of Stockholders’ Equity

​​​​​​​​​​​​​​​​​
​ · ​ · Common stock · ​ · Additional · ​ · ​ · Accumulated other · ​ · ​ · Accumulated · ​ · ​ · ​
(in thousands, except share data) · ​ · Shares · ​ · Amount · ​ · paid‑in capital · ​ · ​ · comprehensive income (loss) · ​ · deficit · ​ · Total
Balance at April 1, 202354,626,690​$5$697,517​$(427)​$(526,744)​$170,351
Exercise of stock options and vesting of restricted stock units18,750​​—​—​​—​​—​​—
Issuance of shares in connection with employee stock purchase plan​100,240​​—​89​​—​​—​​89
Unrealized gain (loss) on marketable securities—​​——​​87​​—​​87
Share‑based compensation expense—​​—​3,743​​—​​—​​3,743
Net loss—​​—​—​​—​​(23,856)​​(23,856)
Balance at June 30, 2023​54,745,680​$5$701,349​$(340)​$(550,600)​$150,414
​​​​​​​​​​​​​​​​​
​​​​​​​​​​​​​​​​​
​​​​​​​​​​​​​​​​​
​​Common stock​Additional​​Accumulated other​​Accumulated​​​
(in thousands, except share data)Shares​Amount​paid‑in capital​​comprehensive income (loss)​deficit​Total
Balance at January 1, 202354,614,690​$5$694,733​$(966)​$(492,406)​$201,366
Exercise of stock options and vesting of restricted stock units​30,750​​—​—​​—​​—​​—
Issuance of shares in connection with employee stock purchase plan​100,240​​—​89​​—​​—​​89
Unrealized gain (loss) on marketable securities​—​​——​​626​​—​​626
Share‑based compensation expense—​​—​6,527​​—​​—​​6,527
Net loss—​​—​—​​—​​(58,194)​​(58,194)
Balance at June 30, 202354,745,680​$5$701,349​$(340)​$(550,600)​$150,414
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.